Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653249 | 0.87 | HPGD (0.38) | HPGDFGFR1SRCGABRA1GABRG2 | |
| SCHEMBL2654543 | 0.78 | HPGD (0.37) | HPGDFGFR1SRCGABRA1GABRG2 | |
| SCHEMBL2654495 | 0.78 | FGFR1 (0.41) | HPGDFGFR1SRCALDH1A1NPC1 | |
| SCHEMBL2654673 | 0.78 | FGFR1 (0.53) | HPGDFGFR1GABRA1GABRG2GABRB3 | |
| SCHEMBL2654510 | 0.78 | GABRA1 (0.40) | HPGDFGFR1SRCGABRA1GABRG2 | |
| SCHEMBL2665437 | 0.76 | GABRA1 (0.41) | HPGDFGFR1SRCGABRA1GABRG2 | |
| SCHEMBL2645149 | 0.76 | HTT (0.39) | HPGDFGFR1GABRA1GABRG2GABRB3 | |
| SCHEMBL2643019 | 0.76 | GABRA1 (0.52) | FGFR1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2654024 | 0.76 | FGFR1 (0.62) | HPGDFGFR1GABRA1GABRG2GABRB3 | |
| SCHEMBL8232331 | 0.76 | MEN1 (0.43) | HPGDFGFR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1613618-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087690-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | GABRB2, GABRB1, GABRB3 | HPGD 2466/4885FGFR1 3374/4885SRC 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.